GCTK vs. NXGL, MBOT, SSKN, PETV, MHUA, BTCY, PSTV, NURO, PAVM, and OSA
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include NEXGEL (NXGL), Microbot Medical (MBOT), STRATA Skin Sciences (SSKN), PetVivo (PETV), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), Plus Therapeutics (PSTV), NeuroMetrix (NURO), PAVmed (PAVM), and ProSomnus (OSA). These companies are all part of the "surgical & medical instruments" industry.
GlucoTrack (NASDAQ:GCTK) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
In the previous week, GlucoTrack had 2 more articles in the media than NEXGEL. MarketBeat recorded 8 mentions for GlucoTrack and 6 mentions for NEXGEL. NEXGEL's average media sentiment score of 0.40 beat GlucoTrack's score of 0.12 indicating that NEXGEL is being referred to more favorably in the news media.
GlucoTrack has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
NEXGEL has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than NEXGEL, indicating that it is currently the more affordable of the two stocks.
10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 2.2% of NEXGEL shares are held by institutional investors. 17.7% of GlucoTrack shares are held by insiders. Comparatively, 27.2% of NEXGEL shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
GlucoTrack has a net margin of 0.00% compared to NEXGEL's net margin of -67.48%. NEXGEL's return on equity of -54.71% beat GlucoTrack's return on equity.
NEXGEL received 1 more outperform votes than GlucoTrack when rated by MarketBeat users.
Summary
NEXGEL beats GlucoTrack on 9 of the 13 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
